Zhejiang Hisun Pharmaceutical
Hisun is a large Chinese maker of active ingredients and generic injectables, founded in 1952 in Taizhou, whose biosimilar and generic cancer medicines go through the phase 3 trials it sponsors.
Overview
Zhejiang Hisun Pharmaceutical, headquartered in Taizhou, Zhejiang, and listed in Shanghai, is one of China's largest producers of active pharmaceutical ingredients and sterile injectables, including anthracyclines and other cytotoxics, and has moved into biosimilars such as adalimumab and bevacizumab. ClinicalTrials.gov lists Hisun as lead sponsor of a phase 3 cancer trial.
Similar pages
not linked directly; found by shared links- CompanyOrganon & Co.
Shares Biosimilar, Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyMabion
Shares Biosimilar, Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyGrifols
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.